drugset / Trial / NCT04339712
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction
Non-randomizedFactorialOpen-labelTreatment
Summary
Our aim is to conduct one trial of personalized immunotherapy in patients with SARS-CoV-2 (COVID-19) associated with organ dysfunction and with laboratory findings of macrophage activation syndrome or immune dysregulation. These patients will be selected by the use of a panel of biomarkers and laboratory findings and they will be allocated to immunotherapy treatment according to their needs.
Timeline
- Start
- 2020-04-02
- Primary completion
- 2020-12-01
- Completion
- 2021-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anakinra | Protein / enzyme biologic | 100 mg | Intravenous |
| Subject | Anakinra | Protein / enzyme biologic | 200 mg | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |